Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : RRD-251
CAS No.: 131916-62-6
Catalog No.: PC-35100Not For Human Use, Lab Use Only.
RRD-251 is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 25 mg | $88 | In stock | |
| 50 mg | $138 | In stock | |
| 100 mg | $218 | In stock | |
| 250 mg | Get quote | ||
| 1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
RRD-251 is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.
RRD-251 inhibits Rb to recruit Raf-1 to proliferative promoters and inhibited E2F1-dependent transcriptional activity.
RRD-251 inhibits anchorage-dependent and anchorage-independent growth of human cancer cells.
RRD-251 significantly inhibits tumor growth in tumors with functional Rb in vivo.
| M.Wt | 235.126 | |
| Formula | C8H8Cl2N2S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
2,4-dichlorobenzyl carbamimidothioate |
|
1. Kinkade R, et al. Cancer Res. 2008 May 15;68(10):3810-8.
2. Singh S, et al. Mol Cancer Ther. 2010 Dec;9(12):3330-41.
3. Treviño JG, et al. Mol Cancer Ther. 2013 Dec;12(12):2722-34.
4. Wallace AS, et al. Oncotarget. 2016 Jul 19;7(29):46401-46418.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
